CD36 and breast cancer: This suggests that the dual inhibition of exogenous FA uptake and endogenous SCD-1-mediated de novo lipogenesis using CD36 and PI3K inhibitors might be a viable therapeutic approach in anti-HER2 resistant breast cancer with PTEN-loss.